ABOUT THE CONFERENCE
INVITATION TO GLOBAL ONCOLOGY AND CANCER SUMMIT - 2020, BANGALORE, INDIA,
On behalf of the organizing committee, we take this opportunity in extending a warm and cordial welcome to you to be a part of the Global Oncology and Cancer Summit. Global Oncology and Cancer Summit – 2020 conference is scheduled during 17th May, 2020, at Bangalore, India. This conference aim is to gather the most elegant societies and industries along with the renowned and honorable persons from top universities across the globe. The Global Oncology and Cancer Summit – 2020 organizing committee is confident that participants will get benefits from this high-value scientific program. We welcome all the researchers/ academicians join us at Bagalore, India.
About 12.7 million cancer cases and 7.6 million cancer deaths are estimated to have occurred in 2008 worldwide, with 56% of the cases and 64% of the deaths in the economically developing world. Breast cancer, the most common tumour in women, presents a high survival percentage: 83% of patients have survived this type of cancer after five years. Lung cancer is one of the most aggressive tumors and survival after five years is very low: only 10% of patients diagnosed with a malignant neoplasm survive for more than five years. Colorectal cancer (of the colon and rectum), the most common malignant tumour if we group men and women together, presents an average survival rate of 50-55% five years after diagnosis, meaning that half the patients survive this form of cancer. Prostate cancer, today the most common tumour in men, has an increasingly favourable prognosis, with a global survival rate of 76%, which is higher in young adults. Ovarian cancer presents a very varied prognosis depending on age: whilst 70% of the group between 15 and 44 years survives this form of cancer, this is the case for only 19% of those over 74 years-old.
The global cancer/tumor profiling market was valued at $13.30 billion in 2012. At the end of 2013, the market is estimated to be $14.99 billion and is poised to reach around $35 billion by 2018, growing at a CAGR of 18.50% from 2013 to 2018. Global oncology spending hit $91 billion for 2013 and it's growing at a 5% clip annually, which will cross $100 billion in 2015. The key players in the cancer/tumor profiling market are Boreal Genomics Inc. (U.S.), Caris Life Sciences (U.S.), Genomic Health Inc. (U.S.), Illumina Inc. (U.S.), Life Technologies Corporation (U.S.), NeoGenomics Laboratories (U.S.), Oxford Gene Technology Ltd. (U.K.), Precision Therapeutics Inc. (U.S.), bioTheranostics (U.S.), Proteome Sciences PLC (U.K.), Agendia (The Netherlands), Nanostring Technologies (U.S.), Rational Therapeutics (U.S.), Oncopath Laboratories (U.S.), and RiboMed BiotechnologiesInc. (U.S.). Global cancer diagnostics market is expected to reach $13.1 Billion in 2020 from an estimated $7.1 Billion in 2015, growing at a CAGR of 12.9%. The market is dominated by North America, followed by Europe, Asia, and Rest of the World (RoW). The cancer diagnostics market in Asia is expected to grow at the highest rate from 2015 to 2020. According to the market the global oncology drugs market is expected to reach at $111.9 billion by 2020. Patent expiration of key cancer drugs such as Herceptin, Erbitux, Rituxan and Avastin, is expected to boost the growth of cancer biosimilars market by 2020.
Global Oncology and Cancer Summit - 2020 is a one day event consisting of a lettered scientific program, laudable talks by the top notch of the global scientific community, that brings together active researchers, intellectuals, academicians, students, contributors and industrialists to exchange ideas communicate and discuss research findings on new advancements in all kinds of available oncology and cancer research worldwide innovative research products which can be exhibited for further development in Oncology. This Global Oncology and Cancer Summit – 2020 is going to be the largest and most promising international conference that specifically focuses on the Oncology, Radiation therapy by bringing all Renowned Oncologists under one roof. This will be the multidisciplinary meeting covering all aspects of Oncology, New Innovation, Cancer Drug Development, Cancer Therapies and Radiation Oncology, including clinical service delivery, management, informatics and research.
Similarly, the conference will show the students a new way for future innovations. The conference also focuses on current research evidence, practical experiences and innovative ideas on issues related to Oncology and Cancer Research
Looking forward to meet with you in Bangalore this Year.
Worldwide Cancer Diagnostics advertise is relied upon to develop from $8.54 billion out of 2016 to reach $22.41 billion by 2023 with a CAGR of 8 %. Expanding frequency of cancer illnesses, developing mindfulness about human services, and later mechanical progressions in symptomatic gadgets are a portion of the elements moving the market development. Moreover, ideal government repayment approaches, expanding interests in innovative work exercises are some different elements boosting the market development amid the estimated time frame.
Then again, high expenses of analytic gadgets, strict controls for new item endorsements are the variables restricting the market development. Just 10% of patients determined to have a harmful neoplasm get by for over five years. Colorectal cancer (of the colon and rectum), the most widely recognized threatening tumor in the event that we amass people together, presents a normal survival rate of 50-55% five years after analysis, implying that a large portion of the patients survives this type of cancer. Prostate cancer, today the most widely recognized tumor in men, has an inexorably great prognosis, with a worldwide survival rate of 76%, which is higher in youthful grown-ups. Ovarian cancer displays an exceptionally shifted prognosis relying upon age: while 70% of the gathering somewhere in the range of 15 and 44 years survives this type of cancer, this is the situation for just 19% of those more than 74 years of age. Consistently omics arranges cancer gatherings in Europe.
The Congress in Bangalore will feature presentations of some of the most recent research and trials including targeted therapies and immunotherapeutic approaches, joint symposia with representatives of all oncology specialties, and robust debates on the clinical challenges oncologists face today. We are expecting practice-changing abstracts and timely data to be presented..
The scientific program this year is intended to cover a spectrum of topics such as cancer awareness, social and economic challenges, complementary medicines, tumor microenvironment, biomarkers, preclinical disease models, emerging treatment paradigms like immunotherapy, precision therapy, and challenges pertaining to drug discovery, development, and transitional research.
I sincerely hope that this conference will deliberate and discuss all the different facets of this exciting topic and come up with recommendations that will lead to a better, healthier, merrier world.
Looking forward to meet with you in Bangalore this Year.
With Warm Regards
Padmashri Dr. K. S. Gopinath,
Consultant Surgurical Oncologist & Director,
Track 1: Cancer
Track 2: Cancer Therapy
Track 3: Organ Specific Cancers
Track 4: Cancer Science
Track 5: Cancer Biomarkers
Track 6: Cancer Diagnosis
Track 7: Radiation Oncology
Track 8: Radiation Therapy
Track 9: Nuclear Medicine
Track 10: Medical Imaging
Track 11: Chemotherapy
Track 12: Cancer Immunology & Immunotherapy
Track 13: Cancer Stem Cell Therapy
Track 14: Cancer Epidemology
Track 15: Cancer Genetics
Track 16: Nanotechnology in Cancer
Track 17: Cancer Drugs
Track 18: Cancer Vaccines
Track 19: Cancer Alternative Medicine
Track 20: Oncology Nursing
Track 21: Clinical Oncology
Track 22: Surgical Oncology
Track 23: Cancer Prevention & Cure
Track 24: Cancer Case Reports
Authors are invited to submit abstract(s) using the submission form on this page. Abstracts should contain sufficient detail on the techniques used and the results, which will be shown. You will receive a confirmation when the abstract has been received. Please contact the conference secretariat if you did not receive confirmation within 5 working days. Submission implies the intent of at least one author to register, attend the symposium and present the paper orally or in poster format. Contributions will only be finally accepted after registration and payment of the conference fee. The abstract will be reviewed, and you will be notified of acceptance.
- The entire body of the abstract, excluding tables, must not exceed 3,800 characters. Spaces are not included in this number. Title, authors’ names, affiliations, figures, and tables are not included in the character count.
- The abstract may be structured (i.e., abstracts divided into sections using terms such as Introduction, Methods, Results, Conclusions, etc.) or unstructured.
- Do not use bold type or underline formatting. Italic type is acceptable.
- Text may be in multiple paragraphs.
- Any references should be noted as citations within the text and not as footnotes at the end
Abstract Submission Deadline: 17th March, 2020
Early Bird Registration Deadline: 11th November, 2019
to Submit Abstract